| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T142 |
0-148 |
Sentence |
denotes |
There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. |
| T143 |
149-245 |
Sentence |
denotes |
These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. |
| T144 |
246-470 |
Sentence |
denotes |
Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. |
| T145 |
471-561 |
Sentence |
denotes |
However, to date, no experimental or clinical data have emerged to support these concerns. |
| T146 |
562-638 |
Sentence |
denotes |
At the same time, the risks of discontinuing these therapies are well known. |
| T147 |
639-817 |
Sentence |
denotes |
Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]. |
